...
首页> 外文期刊>European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology >Induction chemotherapy: to downgrade aggressive cancers to improve curability by surgery and/or radiotherapy.
【24h】

Induction chemotherapy: to downgrade aggressive cancers to improve curability by surgery and/or radiotherapy.

机译:诱导化疗:通过手术和/或放疗降低恶性肿瘤的水平,以提高治愈率。

获取原文
获取原文并翻译 | 示例

摘要

Induction chemotherapy can be effective in reducing locally advanced or aggressive cancers to improve their prospects of cure by planned follow-up surgery and/or radiotherapy. Systemic (intravenous) delivery is the simplest and most readily available method of administering induction chemotherapy. In some situations, a greater chemotherapy impact can be achieved by delivering a more concentrated dose of effective anti-cancer agents into the arterial blood supply of the cancer. Intra-arterial (i.a.) chemotherapy may or may not be advantageous. To achieve an advantage, the tumour must be fully contained in tissue supplied by one or more arteries that can be effectively cannulated and infused. The cancer must also be one known to respond better to concentrated chemotherapy and the agents used must be effective in the state in which they are delivered. The advantages must outweigh the likely increased risks of regional toxicity and experienced personnel and appropriate specialized equipment must be available to reduce any risk of mistakes made by the more exacting techniques of delivery. In general, systemic chemotherapy is most appropriate in treating tumours without a single artery of supply; when certain agents that are inactive until modified in body tissues (such as cyclophosphamide or DTIC) are to be used; when satisfactory responses can be achieved safely and more easily by systemic delivery; when technical skills and facilities for regional delivery are not available; or when the patient's general health, poor co-operation or long-term prognosis precludes the additional complexity of regional delivery. Intra-arterial infusion may have advantages in treating some locally advanced malignancies in the head and neck, a limb, some invasive stomach cancers and some breast cancers. Primary and some metastatic liver cancers, some pelvic cancers and possibly pancreatic malignancies may also respond well to initial direct chemotherapy infusion and are the subject of several studies. Closed circuit perfusion (Creech-Krementz), chemofiltration infusion and "stop-flow" perfusion (Aigner) and regional limb infusion (Thompson) are more complex techniques aimed at even greater localized initial tissue chemotherapy concentrations over a short time span. These are the subject of ongoing studies in highly specialized units. Their use is designed to achieve tumour responses in treating such malignancies as melanoma, some sarcomas or pancreatic cancer that usually show a poor response to standard systemic chemotherapy.
机译:诱导化疗可以有效地减少局部晚期或侵袭性癌症,以通过计划的后续手术和/或放疗来改善其治愈的前景。全身(静脉内)递送是最简单且最容易获得的施用诱导化学疗法的方法。在某些情况下,可以通过将更集中剂量的有效抗癌药输送到癌症的动脉血供中来实现更大的化疗效果。动脉内(i.a.)化疗可能会或可能不会有利。为了获得优势,肿瘤必须完全包含在一个或多个动脉提供的组织中,该组织可以有效地插管和输注。癌症也必须是已知的一种能对集中化疗产生更好反应的癌症,并且所用药物必须在其交付状态下有效。优点必须超过可能增加的区域毒性风险,并且必须有经验丰富的人员,并且必须配备适当的专用设备,以减少由更严格的交货技术所造成的任何错误风险。通常,全身化疗最适合于无单一动脉供应的肿瘤的治疗。当使用在身体组织中直到被修饰才失活的某些药剂时(例如环磷酰胺或DTIC);通过全身给药可以安全,轻松地获得满意的响应时;当无法提供区域交付的技术技能和设施时;或患者的整体健康,合作不佳或长期预后排除了区域分娩的额外复杂性。动脉内输注可能在治疗头部和颈部,肢体的某些局部晚期恶性肿瘤,某些浸润性胃癌和某些乳腺癌方面具有优势。原发性和某些转移性肝癌,某些骨盆癌以及可能的胰腺恶性肿瘤也可能对最初的直接化学疗法输注反应良好,并且是数项研究的主题。闭路灌注(Creech-Krementz),化学滤过灌注和“止流”灌注(Aigner)以及局部肢体灌注(Thompson)是更复杂的技术,旨在在较短的时间范围内实现更高的局部初始组织化学治疗浓度。这些是在高度专业化的单元中正在进行的研究主题。它们的用途旨在在治疗通常对标准全身化疗反应不良的黑色素瘤,某些肉瘤或胰腺癌等恶性肿瘤中实现肿瘤反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号